A high-throughput single-use platform for vaccine bioprocess development

Conference Dates

March 20 – 23, 2022


Vaccination is the predominant tool in the prevention of infectious disease. Considering the SARS-CoV-2 (Covid-19) pandemic, the need for a development platform, capable of rapid candidate screening and/or a vaccine scaffold capable of adaptability to new disease targets, has never been more apparent. VLPs, expressed in the methylotrophic yeast Pichia pastoris, offer an exciting alternative to current manufacturing methods due to their potential as scaffolds for foreign antigen display. The hepatitis B core antigen (HBC) can spontaneously self-assemble, forming icosahedral particles that are inherently immunogenic. Tandem Core HBC (TC-HBC) VLPs have been genetically modified in the major insertion region (MIR) enabling display of up to two epitopes of interest when assembled. For TC-HBC VLPs to be considered a viable vaccine candidate, their bioprocessing must be optimized. Currently, there are various issues to address, including problems with formation, solubility, and immunogenicity.

Please click Additional Files below to see the full abstract.

27.pdf (158 kB)

This document is currently not available here.